Journal of Cardiac Failure
Volume 14, Issue 1 , Pages 27-34 , February 2008

The Relationship Between Anemia, Change in Hematocrit Over Time and Change in Health Status in Patients With Heart Failure After Myocardial Infarction

  • Mikhail Kosiborod, MD

      Affiliations

    • Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri
    • ,
  • Harlan M. Krumholz, MD, SM

      Affiliations

    • Yale University, New Haven, Connecticut
    • ,
  • Philip G. Jones, MS

      Affiliations

    • Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri
    • ,
  • Bertram Pitt, MD

      Affiliations

    • University of Michigan, Ann Arbor, Michigan
    • ,
  • John A. Spertus, MD, MPH

      Affiliations

    • Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri
    • Corresponding Author InformationReprint requests: John A. Spertus, MD, MPH, Mid America Heart Institute, 4401 Wornall Road, Kansas City, MO 64111.

Received 22 May 2007 ,Revised 23 September 2007 ,Accepted 27 September 2007.

References 

  1. American Heart Association. Heart Disease and Stroke Statistics—2005 Update.
  2. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. [comment] J Am Coll Cardiol. 2001;38:955–962
  3. Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, et al. Anemia and its relationship to clinical outcome in heart failure. Circulation. 2004;110:149–154
  4. Felker GM, Gattis WA, Leimberger JD, Adams KF, Cuffe MS, Gheorghiade M, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol. 2003;92:625–628
  5. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. [comment] J Am Coll Cardiol. 2002;39:1780–1786
  6. Kosiborod M, Curtis JP, Wang Y, Smith GL, Masoudi FA, Foody JM, et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med. 2005;165:2237–2244
  7. Mozaffarian D, Nye R, Levy WC. Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol. 2003;41:1933–1939
  8. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol. 2002;13:1928–1936
  9. Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. [comment] Circulation. 2003;107:223–225
  10. Sharma R, Francis DP, Pitt B, Poole-Wilson PA, Coats AJ, Anker SD. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J. 2004;25:1021–1028
  11. Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM. The prognostic importance of anemia in patients with heart failure. Am J Med. 2003;114:112–119
  12. Spertus JA, Tooley J, Jones P, Poston C, Mahoney E, Deedwania P, et al. Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study). Am Heart J. 2002;143:636–642
  13. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321
  14. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35:1245–1255
  15. Heidenreich PA, Spertus JA, Jones PG, Weintraub WS, Rumsfeld JS, Rathore SS, et al. Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol. 2006;47:752–756
  16. Soto GE, Jones P, Weintraub WS, Krumholz HM, Spertus JA. Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation. 2004;110:546–551
  17. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J. 2005;150:707–715
  18. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, et al. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation. 2005;112:1121–1127
  19. Anand IS, Chandrashekhar Y, Ferrari R, Poole-Wilson PA, Harris PC. Pathogenesis of oedema in chronic severe anaemia: studies of body water and sodium, renal function, haemodynamic variables, and plasma hormones. [comment] Br Heart J. 1993;70:357–362
  20. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577–585
  21. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775–1780
  22. Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. [comment] Circulation. 2003;107:294–299
  23. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  24. U.S. National Institutes of Health ClinicalTrials.gov: Red-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial. Available at: http://clinicaltrials.gov/ct/show/NCT00358215. Accessed September 20, 2007.
  25. Silverberg DS, Wexler D, Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail. 2002;4:681–686

 Funding Source: Funding for this study was provided by Pfizer, Inc., New York, NY.

 Conflict of Interest Disclosures: Dr. Spertus discloses that he developed and owns the copyright to the Kansas City Cardiomyopathy Questionnaire; is a consultant for Amgen, United Healthcare, and Otsuka; and receives research grant support from the National Institutes of Health, Amgen, Lilly, Roche Diagnostics, Atherotech, and the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). Dr. Krumholz discloses that he has research contracts with the Colorado Foundation for Medical Care and the American College of Cardiology, serves on the advisory boards for Amgen, Alere and United Healthcare, is a subject matter expert for VHA, Inc., and is Editor-in-Chief of Journal Watch Cardiology of the Massachusetts Medical Society. Dr. Pitt discloses that he is a consultant for Pfizer and Novartis.

PII: S1071-9164(07)01084-6

doi: 10.1016/j.cardfail.2007.09.009

Journal of Cardiac Failure
Volume 14, Issue 1 , Pages 27-34 , February 2008

Article Tools

* Image Usage & Resolution